Cancer Treatment Reviews
Volume 25, Issue 4 , Pages 219-227 , August 1999

The potential of melanoma antigen expression in cancer therapy

References 

    REFERENCES
  1. Coley WB. The treatment of malignant tumours by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893;105:487
  2. Gross L. Intradermal immunisation of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 1943;31:326–333
  3. Foley EJ. Antigenic properties of methylcholanthrene-induced tumours in mice of the strain of origin. Cancer Res. 1953;13:835–837
  4. Prehn RT and Main JM. Immunity to methylcholanthrene-induced sarcomas. J Nat Cancer Inst. 1957;18:769–778
  5. Hewitt HB, Blake ER and Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 1976;33:241–259
  6. Lewis JL and Houghton AN. Definition of tumour antigens suitable for vaccine construction. Semin Cancer Biol. 1995;6:321–327
  7. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–1647
  8. Boon T. Teaching the immune system to fight cancer. Sci-Am. 1993;268:82–89
  9. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora J-P, De Smet C, et al. Structure chromosomal localization and expression of 12 genes of the MAGE family. Immunogenetics. 1994;40:360–369
  10. Oaks MX, Hanson JP, O’ Malley DP. Molecular cytogenetic mapping of the human melanoma antigen (MAGE) gene family to chromosome region Xq27-qter: implications for MAGE immunotherapy. Cancer Res. 1994;54:1627–1629
  11. Muscatelli F, Walker AP, De Plaen E, Stafford AN and Monaco AP. Isolation and characterization of a MAGE gene family in the Xp2 1.3 region. Proc Natl AcadSci USA. 1995;92:4987–4991
  12. Imai Y, Shichijo S, Yamada A, Katayama T, Y ano H and Itoh K. Sequences analysis of the MAGE gene family encoding human tumor-rejection antigens. Gene. 1995;160:287–290
  13. Ding M, Beck RJ, Keller CJ and Fenton RG. Cloning and analysis of MAGE1 related genes. Biochem Biophys Res Commun. 1994;202:549–555
  14. Rogner UC, Wilke K, Steck E, Korn B, Poustka A. The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics. 1995;29:725–731
  15. Amar-Costesec A, Godelaine D, Stockert E, van der Bruggen P, Beaufay H and Chen YT. The tumor protein MAGE-1 is located in the cytosol of human melanoma cells. Biochem Biophys Res Commun. 1994;204:710–715
  16. Schultz-Thater E, Juretic A, Dellabona P. Luscher U, Siegrist W, Harder F, Heberer M, Zubre M and Spagnoli GC. MAGE-1 gene product is a cytoplasmic protein. Int J Cancer. 1994;59:435–439
  17. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res. 1995;55:2236–2239
  18. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, et al. A nonapeptide encoded by human gene MAGE-1 is recognised on HLA-A 1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992;176:1453–1457
  19. van der Bruggen P, Szikora J-P, Boel P, Wildmann C, Somville M, Sensi M, et al. Autologous cytolytic T lymphocytes recognise a MAGE-1 nonapeptide on melanomas expressing HLA-Cw(*)1601. Eur J Immunol. 1994;24:2134–2140
  20. Gaugler B, Van Den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, et al. Human gene MAGE-3 codes for an antigen recognised on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994;179:921–930
  21. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognise tumor cells expressing MAGE-3. Eur J Immunol. 1994;24:3038–3043
  22. Celis E, Fikes J, Wentworth P, Sidney J, Southwood S, Maewal A, et al. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol. 1994;31:1423–1430
  23. Luescher IF, Romero P, Kuznetsov D, Rimoldi D, Coulie P, Cerottini JC, et al. HLA photoaffinity labeling reveals overlapping binding of homologous melanoma associated gene peptides by HLA-A1, HLA-A29, and HLA-B44. J Biol Chem. 1996;271:12463–12471
  24. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res. 1995;55:3478–3482
  25. Mulcahy KA, Rimoldi D, Brasseur F, Rodgers S, Lienard D, Marchand M, et al. Infrequent expression of the MAGE gene family in uveal melanomas. Int J Cancer. 1996;66:738–742
  26. Chen PW, Murray TG, Salgaller ML, Ksander BR. Expression of MAGE genes in ocular melanoma cell lines. J Immunother. 1997;20:265–275
  27. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis. 1997;15:509–518
  28. Corrias V, Scaruffi P, Occhino M, De Bemardi B, Tonini GP, Pistoia V. Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer. 1996;69:403–407
  29. Ishida H, Matsumura T, Salgalire ML, Ohmizono Y, Kadono Y, Sawada T. MAGE-1 and MAGE-3 or – 6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer. 1996;69:375–380
  30. Shichijo S, Tsunosue R, Masuoka K, Naton H, Tamai M, Miyajima J, et al. Expression of the MAGE gene family in human lymphocytic leukemia. Cancer Immunol Immunother. 1994;41:90–103
  31. Carrel S, Schreyer M, Spagnoli G, Cerottini JC and Rimoldi D. Monoclonal antibodies against recombinant MAGE-1 protein identify a cross-reacting 72-kDa antigen which is co-expressed with MAGE- 1 protein in melanoma cells. Int J Cancer. 1996;67:417–422
  32. Yamada A, Kataoka A, Shichijo S, Kamura T, Imai Y, Nishida T and Itoh K. Expression of MAGE- 1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumours. Int J Cancer. 1995;64:388–393
  33. Kuramoto T. Detection of MAGE-1 tumor antigen in brain tumor. Kurume Med J. 1997;44:43–51
  34. Gudat F, Zuber M, Durmuller U, Kocher T, Schaefer C, Noppen C, et al. The tumour associated antigen MAGE-1 is detectable in formalin-fixed paraffin sections of malignant melanoma. Virchows Arch. 1996;429:77–81
  35. Shichijo S, Hoshino T, Koufuki K, Hayashi A, Kawamoto M, Kikuchi M, et al. Detection of MAGE-4 protein in sera of lung cancer patients. Jpn J Cancer Res. 1997;88:414–419
  36. Iwamoto O, Nagao Y, Shichijo S, Eura M, Kameyama T, Itoh K. Detection of MAGE-4 protein in sera of patients with head and neck squamous cell carcinoma. Int J Cancer. 1997;70:287–290
  37. Toh Y, Yamana H, Shichijo S, Fujita H, Tou U, Sakaguchi M, et al. Expression of MAGE-1 gene by esophageal carcinomas. Jpn J Cancer Res. 1995;86:714–717
  38. Patard J-J, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, Francois P, et al. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer (PredOncol). 1995;64:60–64
  39. Shichijo S, Hayashi A, Takamori S, Tsunosue R, Hoshino TR, Sakata M, et al. Detection of MAGE-4 protein in lung cancers. Int J Cancer. 1995;64:158–165
  40. Mori M, Inoue H, Mimori K, Shibuta K, Baba K, Nakashima H, et al. Expression of MAGE genes in human colorectal carcinoma. Ann Surg. 1996;224:183–188
  41. Eura M, Ogi K, Chikamatsu K, Lee KD, Nakano K, Masuyama K, et al. Expression of the MAGE gene family in human head and neck squamous cell carcinomas. Int J Cancer. 1995;64:304–308
  42. Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel S, Arienti F, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer. 1995;63:375–380
  43. Katano M, Nakamura M, Morisaki T, Fujimoto K. Melanoma antigen-encoding gene- 1 expression in invasive gastric carcinoma: correlation with stage of disease. J Surg Oncol. 1997;64:195–201
  44. Russo V, Traversari C, Verrecchia A, Mottolese M, Natali PG and Bordignon C. Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer. 1995;64:216–221
  45. Inoue H, Mori M, Li J, Mimori K, Honda M, Nakashima H, et al. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer. 1995;63:523–526
  46. Gillespie AM, Rodgers S, Wilson AP, Tidy J, Rees RC, Coleman RE and Murray AK. MAGE, BAGE and GAGE: Tumour antigen expression in benign and malignant ovarian tissue. Br J Cancer. 1998;78:816–821
  47. Becker JC, Gillitzer R, Brocker EB. A member of the melanoma antigen-encoding gene (MAGE) family is expressed in human skin during wound healing. Int J Cancer. 1994;58:346–348
  48. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, et al. Expression of MAGE- 1 tumor antigen as up-regulated by the demethylating agent 5-aza-21-deoxycytidine. Cancer Res. 1994;54:1766–1771
  49. Schichijo S, Yamada A, Sagawa K, Iwamoto O, Sakata M, Nagai K and Itoh K. Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-21-deoxycytidine. Jpn J Cancer Res. 1996;87:751–756
  50. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F and Boon T. The activation of human gene MAGE- 1 in tumor cells is correlated with genomewide demethylation. Proc Natl Acad Sci USA. 1996;93:7149–7153
  51. Serrano A, Garcia A, Abril E, Garrido F, Ruiz-Cabello F. Methylated CpG points identified within MAGE-1 promoter are involved in gene repression. Int J Cancer. 1996;68:464–470
  52. Uyttenhove C, Godfraind C, Lethe B, Amar-Costesec A, Renauld JC, Gajewski TF, et al. The expression of mouse gene PiA in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer. 1997;70:349–356
  53. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Nat Acad Sci USA. 1994;91:2105–2109
  54. Toso JF, Oei C, Oshidari F, Tartaglia J, Paoletti E, Lyerly JK, et al. MAGE-1 specific precursor cytotoxic T lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen specific activation. Cancer Res. 1996;56:16–20
  55. Valmori D, Lienard D, Waanders G, Rimoldi D, Cerottini JC, Romero P. Analysis of MAGE-3 specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res. 1997;57:735–741
  56. Yamasaki S, Okino T, Chakraborty NG, Adkisson WO, Sampieri A, Padula SJ, et al. Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage colony stimulating factor cultured macrophages from HLA-A1 melanoma patients. Cancer Immunol Immunother. 1995;40:268–271
  57. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA. 1995;92:8078–8082
  58. Hu X, Chakraborty NG, Spron JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocytes precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 1996;56:2479–2483
  59. Hoon DS, Yuzuki D, Hayashida M, Morton DL. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J lmmunol. 1995;154:730–737
  60. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani F, et al. Tumor regression responses in melanoma patients treated with a peptide encode by gene MAGE-3. Int J Cancer. 1995;63:883–885
  61. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumour vaccines with melanoma-associated antigens. Int J Cancer. 1996;66:162–169
  62. Jaeger E, Ringhoffer M, Dienes HP, Aranol M, Karbach J, Jager D, et al. Granulocyte-macrophage-colonystimulating factor enhances immune responses to melanoma-associated peptides invivo. Int J Cancer. 1996;67:54–62
  63. Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 1995;13:2016–2109
  64. van Groeningen CJ, Leyva A, O’Brien AM, Gall HE and Pinedo HM. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986;46:4831–4836
  65. Petti MC, Mandelli F, Zagonel V, De-Gregoris C, Morola MC, Latagliata R, et al. Pilot study of 5-aza-21-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia. 1993;7:36–41
  66. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, et al. BAGE: a new gene encoding on antigen recognised on human melanomas by cytolytic T lymphocytes. Immunity. 1995;2:167–175
  67. Van den Eynde B, Peeters O, De-Backer O, Gaugler B, Lucas S and Boon T. A new family of genes coding for an antigen recognised by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 1995;182:689–698
  68. Fujie T, Mori M, Ueo H, Sugimachi K and Akiyoshi T. Expression of MAGE and BAGE genes in Japanese breast cancers. Annals of Oncology. 1997;8:369–372
  69. Inoue H, Mori M, Honda M, Li J, Shibuta K, Mimori K, et al. The expression of tumour-rejection antigen “MAGE” genes in human gastric carcinoma. Gastroenterology. 1995;109:1522–1525
  70. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol. 1997;150:2143–2152
  71. Lee KD, Eura M, Ogi K, Nakano K, Chikamatsu K, Masuyama K and Ishikawa T. Expression of the MAGE-1, -2, -3, -4 and -6 genes in non-squamous cell carcinoma lesions of the head and neck. Acta Otolaryngol Stockh. 1996;116:633–639
  72. Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K and Niho Y. High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology. 1996;24:1437–1440
  73. Weynants P, Lethé B, Brasseur F, Marchand M and Boon T. Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer. 1994;56:826–829
  74. Sakata M. Expression of MAGE gene family in lung cancers. Kurume Med J. 1996;43:55–61
  75. Eura M, Chikamatsu K, Ogi K, Nakano K, Masuyama K and Ishikawa T. Expression of genes MAGE-1, -2 and -3 by human maxillary carcinoma cells. Anticancer Res. 1995;15:55–59
  76. Quillien V, Raoul JL, Heresbach D, Collet B, Toujas L and Brasseur F. Expression of MAGE genes in osophageal squamous-cell carcinoma. Anticancer Res. 1997;17:387–391
  77. Sudo T, Kuramoto T, Komiya S, Inoue A and Itoh K. Expression of MAGE genes in osteosarcoma. J Orthop Res. 1997;15:128–132
  78. Lurquin C, De-Smet C, Brasseur F, Muscatelli F, Martelange V, De Plaen E, et al. Two members of the human MAGEB gene family located in Xp21–3 are expressed in tumours of various histological origins. Genomics. 1997;46:397–408
  79. Lucas S, De-Smet C, Arden KC, Viars CS, Lethe B, Lurquin C and Boon T. Identification of a new MAGE gene with tumour-specific expression by representational difference analysis. Cancer Res. 1998;58:743–752

☆ Correspondence to: Dr R. E. Coleman.

PII: S0305-7372(99)90126-3

doi: 10.1053/ctrv.1999.0126

Cancer Treatment Reviews
Volume 25, Issue 4 , Pages 219-227 , August 1999

Article Tools